NDAIntravesical, UreteralSolution
Approved
Apr 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
CYSTO-CONRAY (iothalamate meglumine) by Guerbet is clinical pharmacology the most important characteristic of contrast media is the iodine content. First approved in 1972.
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYSTO-CONRAY is an iothalamate meglumine contrast media administered intravesically or ureteral for retrograde urography visualization of the lower urinary tract. The drug's radiodensity is derived from its high iodine content, enabling clear radiographic imaging. Less than 1% is typically absorbed systemically, though up to 12% absorption can occur with pyelorenal backflow.
LOE Approaching
This legacy diagnostic product faces declining utilization as imaging technologies evolve; expect small, specialized commercial teams managing niche radiology markets.
Mechanism of Action
CLINICAL PHARMACOLOGY The most important characteristic of contrast media is the iodine content. The relatively high atomic weight of iodine contributes sufficient radiodensity for radiographic contrast. Following instillation by sterile catheter, Cysto-Conray II provides for visualization of the…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CYSTO-CONRAY offers limited career growth opportunities as a legacy diagnostic product with minimal market expansion potential. Roles on this franchise focus on maintaining market share in specialized radiology centers and managing gradual revenue decline rather than innovation or scale.
Product Manager (Diagnostics)
Worked on CYSTO-CONRAY at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.